A triad between sex, necrosis, and inflammation shapes glioblastoma outcomes
Neuro-Oncology · 2024
DOI: 10.1093/neuonc/noae086 ↗Kurz gefasst
Editorial in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Brandon Emanuel León und 1 weiteren Autor:innen. Beteiligte Einrichtung: Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA. Hauptthemen laut MEDLINE: Glioblastoma, Necrosis, Brain Neoplasms, Inflammation. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Sex differences in incidence and outcomes in glioblastoma (GBM) have long been recognized where males exhibit a greater incidence rate, weaker response to treatment, and decreased survival.1 While hormonal, metabolic, and immunological sex differences have all been shown to contribute to this disparity,2 a deeper understanding of these mechanisms is needed to tailor therapeutic approaches for males and females. In the current study, Vallina et al. define a potential link between sex differences in necroinflammation and treatment response.3 First, the authors analyzed The Cancer Genome Atlas (TCGA) to determine whether expression levels of the sex hormone receptors, estrogen receptors α/β (ESR1/2) and androgen receptor (AR), are correlated with overall survival. ESR2 and AR expression levels did not differ between males and females nor correlated with outcomes. In contrast, ESR1 expression was lower among males compared to females, and higher ESR1 levels positively correlated with the survival of male GBM patients. The authors corroborated these findings in their own GBM cohort leading them to investigate how greater ESR1 expression may impart protection against tumor aggressiveness. To explore the potential mechanisms by which ESR1 impacts survival in male GBM patients, the authors revisited the TCGA GBM data set to identify pathways correlated with ESR1. While hypoxia and necrotic pathways were negatively correlated with ESR1 expression, regulation of angiogenesis was the top upregulated pathway. Additionally, ESR1 expression was enriched in the tumor vascular zone and negatively associated with angiopoietin 2 (ANGPT2). ANGPT2 is a critical mediator of vascular integrity, and ANGPT2 activity increases vessel leakiness and promotes pericyte dropout.4 Pertinently, immunohistochemistry staining revealed disparities in blood vessel integrity in male patient samples with low versus high ESR1 expression. Specimens with high ESR1 levels exhibited greater pericyte coverage and tight junctions on blood vessels compared to low ESR1-expressing specimens. These results demonstrate that high ESR1 expression correlates with intact vasculature which is an indicator of a favorable prognosis in GBM.5,6 To determine how these changes in vasculature potentially impact the tumor microenvironment, the authors graded necrosis. Male tumors with low ESR1 expression exhibited a greater degree of necrotic zones compared to high ESR1-expressing tumors. This was unique to males as female tumors with varying ESR1 expression had similar degrees of necrosis (Figure 1). Hypoxia and necrosis have an intertwined relationship in GBM. As tumors invade surrounding tissue, they exceed their vascular supply and locally induce hypoxia and then necrosis.7 This process is associated with tumor aggressiveness and unfavorable prognosis.8 The current study indicates that ESR1 expression stratifies tumors based on their vascular integrity in which low ESR1 expression tumors are defined by leaky and compromised vessels. Thus, ESR1 expression can inform male patient prognosis through the regulation of tumor vasculature, which subsequently impacts hypoxia and necrosis. Based on these observations, the authors then sought to determine how hypoxia and necrosis shape the tumor microenvironment since necrosis can lead to chronic inflammation. RNA sequencing of tumors with high versus low necrosis revealed a transcriptional profile enriched in inflammatory response and immune cell recruitment. Subsequent immunohistochemical stains examining the immune infiltration profile in tumor core versus necrotic zones demonstrated the accumulation of S100A9-positive cells. These cells were positive for CD11b and negative for major histocompatibility complex II indicating that they are likely myeloid-derived suppressor cells (MDSCs) (Figure 1). Previous studies have shown that MDSCs are recruited in tissues exhibiting chronic inflammation and promote immunosuppression.9 Further, monocytic MDSCs are specifically enriched in male GBM and negatively affect survival,10 suggesting that necrosis-driven MDSC accumulation is a potential mechanism for worsened diseases in males. To determine whether necrotic and inflammatory gene signatures are associated with survival, the authors classified their GBM cohort into necroinflamed males, non-necroinflamed males, and females using a signature based on inflammatory and necrotic genes that were co-upregulated with S100A9. They found that males with necroinflamed tumors exhibited the worst survival compared to males with non-necroinflamed tumors and females. These results demonstrate that necrosis in male tumors is associated with a transcriptomic landscape defined by inflammation and infiltration, which could serve as a predictive biomarker. Interactions between sex, inflammation, and necrosis stratify GBM microenvironment, aggressiveness, and bevacizumab (BVZ) responsiveness (created with BioRender.com). GBM, glioblastoma; MDSC, myeloid-derived suppressor cell. Interestingly, the authors found an inverse relationship between ESR1 and vascular endothelial growth factor A (VEGFA) expression. They further observed that males with high expression of VEGFA exhibited decreased survival compared to males with low VEGFA and females. These prompted them to analyze the potential link between bevacizumab and necroinflammation. Bevacizumab did not impact survival in patients with high VEGFA expression, but improved the outcome of patients with tumors classified as necroinflammed. To further demonstrate that bevacizumab efficacy is dependent on necroinflammation tumor status, the authors transplanted male and female mice with necroinflammed patient-derived xenografts and treated with bevacizumab. Interestingly, they found control female mice had greater survival compared to control males. Bevacizumab treatment improved survival in males which was associated with a decrease in the necroinflammation signature used to classify human necroinflammation (Figure 1). These results show that bevacizumab efficacy is dependent on sex and tumor necroinflammation status rather than inhibiting VEGFA activity and angiogenesis. Disparities between male and female outcomes are an outstanding problem in GBM. Limited insight into the sex-specific disease mechanisms dampens our ability to effectively target unique pro-tumorigenic pathways. To this end, the authors identified a previously unrecognized link between necrosis and inflammation, which is informed by ESR1 expression. While the mechanisms by which ESR1 or VEGFA regulate necroinflammation in a sex-specific manner remain to be studied, these results highlight that sex differences in tumor microenvironment can impact treatment response and serve as a biomarker. None declared.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
- Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, Florida, USA.
ORCID-Profile: Defne Bayik
Zitieren
APA
León, B. E., & Bayik, D. (2024). A triad between sex, necrosis, and inflammation shapes glioblastoma outcomes. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae086
Vancouver
León BE, Bayik D. A triad between sex, necrosis, and inflammation shapes glioblastoma outcomes. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae086
BibTeX
@article{Len2024,
author = {León, Brandon Emanuel and Bayik, Defne},
title = {A triad between sex, necrosis, and inflammation shapes glioblastoma outcomes},
journal = {Neuro-Oncology},
year = {2024},
doi = {10.1093/neuonc/noae086}
}
EUVIMED